> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Iovance Raises Full-Year Revenue Guidance By $55 Million, Citing Record Amtagvi Demand
- URL: https://www.bullished.co/iovance-raises-full-year-revenue-guidance-by-55-million-citing-record-amtagvi-demand-bfd63f8d/
- Published: 2026-10-02T16:35:55.000Z
- Updated: 2026-10-03T20:38:50.000Z
- Description: The biotech lifted its 2026 outlook to $410–$420 million, implying nearly 60% annual revenue growth, in a Tuesday 8-K filing.
- Author: Matteo Parrino
- Tags: SEC Filings, IOVA, Industry: Healthcare

Iovance Biotherapeutics [raised its full-year 2026 revenue guidance](https://www.sec.gov/Archives/edgar/data/0001425205/000110465926111583/tm2626507d1%5F8k.htm?ref=bullished.co) to a range of $410 to $420 million on Tuesday, up from a prior range of $350 to $370 million, citing surging demand for its cancer cell therapy Amtagvi and its Proleukin product. The $55 million increase at the midpoint — about 15% above the previous outlook — implies nearly 60% annual growth in total revenue, according to the company's press release filed with the SEC.

## What The 8-K Says

The guidance update arrived Tuesday via an 8-K current report filed with the SEC, with a press release attached as Exhibit 99.1\. The new range of $410 to $420 million replaces the prior range of $350 to $370 million that Iovance had set with its second-quarter results.

Interim President and CEO Frederick Vogt, Ph.D., J.D., pointed directly to the second quarter as the catalyst. "Our record second quarter and sustained demand for Amtagvi and Proleukin led us to raise our full year 2026 total revenue guidance by $55 million at the midpoint," he said in the [press release](https://www.sec.gov/Archives/edgar/data/0001425205/000110465926111583/tm2626507d1%5Fex99-1.htm?ref=bullished.co). The company most recently reported record second-quarter 2026 total product revenue of $99.3 million.

Vogt added that forward visibility is strong: "Increasing patient demand and our current manufacturing schedule provide strong visibility into our third and fourth quarter revenues."

## The Amtagvi Commercial Engine

Amtagvi — known generically as lifileucel — is the first FDA-approved, one-time treatment for previously treated advanced melanoma and carries approval in three global markets. The therapy is a tumor infiltrating lymphocyte, or TIL, cell therapy, meaning it is manufactured from a patient's own immune cells extracted from a tumor sample.

Iovance has built its authorized treatment center network to roughly 100 locations and said it remains on track to expand to at least 110 by the end of 2026\. The company describes itself as an end-to-end cell therapy company with fully owned, centralized U.S.-based manufacturing, and Vogt said in the release that "continued manufacturing and operating efficiencies accelerate our progress toward profitability."

Beyond melanoma, lifileucel is advancing through late-stage trials targeting additional solid tumor indications, including gene-edited and IL-12 tethered TIL therapies. The press release describes those as "registrational programs in new solid tumor indications" — meaning they are designed to support future regulatory approval applications.

## What It Changes For Holders

The guidance raise completes a review Iovance said it had announced alongside its second-quarter 2026 results. For holders, the key mechanical shift is the revenue floor: the low end of the new range, at $410 million, sits $40 million above the top of the old range.

If the company hits the midpoint of its new guidance — $415 million — that would represent nearly 60% growth over the prior year's total revenue, as the company itself stated. The path to profitability Vogt referenced depends on manufacturing and operating efficiencies continuing to improve as patient volumes grow.

IOVA shares slipped about 0.35% to $14.18 in Friday trading, after having surged on Tuesday when the guidance raise was announced, according to market data.

## What To Watch

Iovance expects to report third-quarter 2026 financial results in early November 2026\. That report will be the first test of whether the raised guidance range holds as manufacturing capacity and patient demand continue to scale.

The authorized treatment center count — roughly 100 now, with at least 110 targeted by year-end — will also be a metric to track, since the network's reach directly determines how many patients can access a therapy that requires specialized administration.

Third-quarter results, expected in early November 2026, will show whether the $410–$420 million range is a floor or a ceiling.

### Sources

- [8-K Filing — IOVANCE BIOTHERAPEUTICS, INC. (IOVA)](https://www.sec.gov/Archives/edgar/data/0001425205/000110465926111583/tm2626507d1%5F8k.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit tm2626507d1\_ex99-1.htm — IOVANCE BIOTHERAPEUTICS, INC. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001425205/000110465926111583/tm2626507d1%5Fex99-1.htm?ref=bullished.co) — SEC EDGAR
- [IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026](https://finance.yahoo.com/markets/stocks/articles/iova-stock-hits-52-week-132200119.html?ref=bullished.co) — finance.yahoo.com
- [Iovance shares jump in premarket as raised outlook clears consensus views](https://finance.yahoo.com/healthcare/articles/iovance-shares-jump-premarket-raised-132346384.html?ref=bullished.co) — finance.yahoo.com
- [Iovance Biotherapeutics, Inc. (IOVA) Stock Price, News, Quote & History - Yahoo Finance](https://ca.finance.yahoo.com/quote/IOVA/?ref=bullished.co) — ca.finance.yahoo.com
- [Iovance Biotherapeutics Appoints Noah Berkowitz, M.D.,](https://www.globenewswire.com/news-release/2026/10/01/3372718/0/en/iovance-biotherapeutics-appoints-noah-berkowitz-m-d-ph-d-as-chief-medical-officer.html?ref=bullished.co) — globenewswire.com
- [Iovance Biotherapeutics Raises Full Year 2026 Revenue](https://www.globenewswire.com/news-release/2026/09/29/3370675/0/en/iovance-biotherapeutics-raises-full-year-2026-revenue-guidance-to-410-to-420-million.html?ref=bullished.co) — globenewswire.com